Hydroxyurea-The Good, the Bad and the Ugly

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Hydroxyurea (HU) is a ribonucleotide reductase (RNR) inhibitor, widely used in treating myeloproliferative disorders and sickle cell anemia.
• HU induces S-phase arrest by causing replication stress and is also explored for Alzheimer's disease cognitive decline prevention.
• Its reversibility aids cell cycle synchronization in labs, but prolonged use can lead to DNA damage, oxidative stress, and potential skin cancer progression.

Purpose of the Study:

• To review the current understanding of hydroxyurea's cytotoxic mechanisms.
• To explore the implications of its less specific enzyme interactions.
• To identify potential new applications based on recent findings.

Main Methods:

• Literature review of existing studies on hydroxyurea.
• Analysis of hydroxyurea's effects on DNA replication and cell cycle progression.
• Examination of hydroxyurea's cytotoxic pathways, including DNA damage and oxidative stress.

Main Results:

• Hydroxyurea effectively inhibits RNR, leading to S-phase arrest and replication stress.
• Prolonged or high-dose HU treatment results in significant DNA damage and oxidative stress, causing cell death.
• Emerging evidence suggests HU may affect multiple enzymes, contributing to varied cellular responses and potential side effects like skin cancer.

Conclusions:

• Hydroxyurea's dual nature as a therapeutic agent and cytotoxic compound requires careful management.
• Understanding its broader enzymatic interactions is crucial for optimizing its use and mitigating adverse effects.
• Further research into HU's mechanisms may unlock novel therapeutic strategies and enhance existing treatments.